| 杨 晶,张庆桥,魏 宁,崔艳峰,许 伟,徐 浩,魏莲子.DEB-TACE联合卡瑞利珠单抗治疗中晚期肝癌的临床疗效及对肿瘤标志物和T淋巴细胞亚群的影响[J].现代生物医学进展英文版,2023,(18):3596-3600. |
| DEB-TACE联合卡瑞利珠单抗治疗中晚期肝癌的临床疗效及对肿瘤标志物和T淋巴细胞亚群的影响 |
| Clinical Efficacy of DEB-TACE Combined with Carrelizumab in the Treatment of Advanced Liver Cancer and Its Influence on Tumor Markers and T Lymphocyte Subsets |
| Received:March 03, 2023 Revised:March 26, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.18.039 |
| 中文关键词: 载药微球-肝动脉化疗栓塞术 卡瑞利珠单抗 中晚期肝癌 疗效 肿瘤标志物 T淋巴细胞亚群 动脉灌注 |
| 英文关键词: Drug-eluting beads-transarterial chemoembolization Carrelizumab Advanced liver cancer Efficacy Tumor markers T lymphocyte subsets Arterial infusion |
| 基金项目:江苏省医学会科研专项基金项目（2021028） |
|
| Hits: 500 |
| Download times: 358 |
| 中文摘要: |
| 摘要 目的：探讨载药微球-肝动脉化疗栓塞术（DEB-TACE）联合卡瑞利珠单抗治疗中晚期肝癌的临床疗效及对肿瘤标志物和T淋巴细胞亚群的影响。方法：采用随机数字表法，将徐州医科大学附属医院于2019年7月-2020年7月期间收治的80例中晚期肝癌患者分为对照组（DEB-TACE治疗，n=40）和研究组（对照组的基础上接受经肝动脉灌注卡瑞利珠单抗治疗，n=40）。对比两组疗效、血清肿瘤标志物、T淋巴细胞亚群指标的变化情况和总生存期（OS）、无进展生存期（PFS），并观察两组不良反发生情况。结果：研究组的客观缓解率（ORR）、疾病控制率（DCR）均高于对照组（P<0.05）。两组治疗1个月后CD8+下降，且研究组低于对照组同期（P<0.05），CD3+、CD4+、CD4+/CD8+升高，且研究组高于对照组同期（P<0.05）。两组治疗1个月后甲胎蛋白（AFP）、异常凝血酶原（PIVKA-II）下降，且研究组低于对照组同期（P<0.05）。研究组的OS（中位OS为13.3个月，2年生存率30.00%）、PFS（中位OS为8.2个月，2年生存率17.50%），均长于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：DEB-TACE联合经肝动脉灌注卡瑞利珠单抗治疗中晚期肝癌，可改善免疫功能，降低血清肿瘤标志物水平，安全有效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) combined with carrelizumab in the treatment of advanced liver cancer and its effect on tumor markers and T lymphocyte subsets. Methods: Using a random number table method, 80 patients with advanced liver cancer who were admitted to the Affiliated Hospital of Xuzhou Medical University from July 2019 to July 2020 were divided into control group (DEB-TACE treatment, n=40) and study group (on the basis of the control group, receiving transcatheter arterial infusion of carbalizumab, n=40). The efficacy, changes of serum tumor markers and T lymphocyte subsets, overall survival (OS) and progression-free survival (PFS) were compared in the two groups, and adverse reactions were observed in the two groups. Results: The objective response rate (ORR) and disease control rate (DCR) in the study group were higher than those in the control group (P<0.05). 1 month after treatment, CD8+ decreased in the two groups, and the study group was lower than the control group in the same period (P<0.05); CD3+, CD4+, CD4+/CD8+ increased, and the study group was higher than the control group in the same period (P<0.05). Alpha-fetoprotein (AFP) and abnormal prothrombin (PIVKA-II) decreased in the two groups at 1 month after treatment, and the study group was lower than the control group in the same period (P<0.05). The OS (median OS was 13.3 months, 2-year survival rate 30.00%) and PFS (median OS was 8.2 months, 2-year survival rate 17.50%) in the study group were both longer than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions in the two groups (P>0.05). Conclusion: DEB-TACE combined with transcatheter arterial infusion of carbalizumab in the treatment of advanced liver cancer can improve immune function and reduce the level of serum tumor markers, which is safe and effective. |
|
View Full Text
View/Add Comment Download reader |
| Close |
